JP2006290832A - Skin lotion - Google Patents
Skin lotion Download PDFInfo
- Publication number
- JP2006290832A JP2006290832A JP2005116080A JP2005116080A JP2006290832A JP 2006290832 A JP2006290832 A JP 2006290832A JP 2005116080 A JP2005116080 A JP 2005116080A JP 2005116080 A JP2005116080 A JP 2005116080A JP 2006290832 A JP2006290832 A JP 2006290832A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- bittern
- carrot
- acne
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、アクネ症状の予防・改善効果に優れるとともに、肌荒れ防止・改善効果、保湿効果に優れた皮膚外用剤に関する。更に詳細には、ニガリ及び月桃エキスを必須成分とし、さらにウコンエキス,ニンジンエキス,ヨモギエキスから選択される1種又は2種以上を併用してなる、皮膚外用剤に関する。 The present invention relates to an external preparation for skin which is excellent in the effect of preventing and improving acne symptoms, and also excellent in the effect of preventing and improving rough skin and the effect of moisturizing. More specifically, the present invention relates to a skin external preparation comprising bittern and moon peach extract as essential components and further using one or more selected from turmeric extract, carrot extract and mugwort extract.
アクネは、顔面や背部などの脂腺が多く存在する部分にできる毛包脂腺系の炎症性疾患である。一般に、アクネ発症要因としては、内分泌因子、細菌性因子、及び角化障害因子等があげられる。内分泌因子とは、男性ホルモンの影響で脂腺の機能が活発になり、皮脂分泌が増加してアクネができやすい状態になることである。細菌性因子とは、皮脂を栄養にして増殖したアクネ菌が産生するリパーゼにより、皮脂中のトリグリセライドが加水分解され、生成された遊離脂肪酸が毛包壁を刺激して角化亢進を引き起こすこと、またはアクネ菌がヒアルロニダーゼやプロテアーゼにより炎症を起こすことをいう。さらに角化障害因子とは、毛漏斗部表皮組織の角化亢進により角質細胞が剥離しにくくなるために、毛包が閉塞状態となり、角質細胞や皮脂等の混合物である内部貯留物がスムースに排出されなくなる状態のことをいう。 Acne is an inflammatory disease of the follicular sebaceous gland system that occurs in areas where there are many sebaceous glands such as the face and back. In general, acne onset factors include endocrine factors, bacterial factors, keratinization disorder factors, and the like. The endocrine factor means that the function of the sebaceous glands becomes active due to the influence of male hormones, and sebum secretion increases and acne is easily formed. Bacterial factor means that the triglyceride in sebum is hydrolyzed by lipase produced by acne bacteria that grew by sebum nutrition, and the generated free fatty acid stimulates the hair follicle wall to cause hyperkeratosis, Or acne bacteria are inflamed by hyaluronidase or protease. Furthermore, the keratinization disorder factor is that the keratinocytes become difficult to detach due to increased keratinization of the epidermis tissue of the hair funnel, so that the hair follicles become occluded, and the internal reservoir, which is a mixture of keratinocytes, sebum, etc., smoothly It means a state where it is no longer discharged.
アクネ治療の外用剤としては、上記の各要因に対応して、皮脂抑制・吸収成分、角質軟化・剥離成分、抗菌・殺菌成分、抗炎症成分等を有効成分として配合したローション、乳剤、クリーム、軟膏などが多く用いられている。例えば、サリチル酸等の殺菌剤を配合したもの、エリスロマイシン、テトラサイクリン、グリンダマイシン、硫黄、カンフル、サルファ剤等の抗生物質、抗菌剤、角質剥離剤などが使用されている。しかしながら、一般的な抗生物質、抗菌剤等は、多く使用すると皮膚の有用な微生物までも殺してしまったり、度重なる塗布によりアクネ周辺の皮膚にダメージを与えることが懸念され、これらを防止するために使用量を抑えると十分なアクネ改善効果が得られない。 As an external agent for acne treatment, lotions, emulsions, creams, etc. formulated with active ingredients such as sebum suppression / absorption component, keratin softening / peeling component, antibacterial / bactericidal component, anti-inflammatory component, etc. Many ointments are used. For example, those containing a bactericidal agent such as salicylic acid, antibiotics such as erythromycin, tetracycline, lindamycin, sulfur, camphor and sulfa, antibacterial agents and keratin removers are used. However, general antibiotics, antibacterial agents, etc., may be used to kill even useful microorganisms on the skin or damage the skin around acne due to repeated application. If the amount used is reduced, sufficient acne improvement effect cannot be obtained.
また、角層剥離剤や皮脂抑制・吸収成分は皮膚の乾燥・かさつきを生じさせる場合があり、美容的に好ましいものではない。これらの皮膚ダメージを抑制するために保湿剤を添加すると、べたつきが生じるなど使用感が悪化するという問題があった。 Further, the stratum corneum peeling agent and sebum suppressing / absorbing component may cause dryness and roughness of the skin, which is not cosmetically preferable. When a moisturizer is added to suppress these skin damages, there is a problem that the feeling of use deteriorates such as stickiness.
また、皮膚外用剤分野におけるゲットウエキスの利用については、ゲットウの一種であるタイリンゲットウの生葉を搾汁して粉砕乾燥した細片を有効成分とする入浴剤(特許文献1)、ゲットウの葉又は茎からの抽出液もしくは圧搾液を配合して成る、アクネ及び肌荒れの改善に有効な薬用化粧料(特許文献2)、ゲットウエキス(主に精油)を有効成分として含有する育毛剤又は発毛剤(特許文献3)等が開示され、最近では、ゲットウ葉エキスの線維芽細胞増殖促進作用,コラーゲン産生促進作用,コラゲナーゼ阻害作用が報告されるなど(非特許文献1)、ゲットウエキスの様々な効果が注目されている。 Moreover, about utilization of the ghetto extract in the skin external preparation field | area, the bath agent (patent document 1) which uses as an active ingredient the strip which squeezed the raw leaf of Tyling ghetto which is a kind of ghetto and pulverized and dried, or a ghetto leaf or A hair-growth agent or hair growth agent containing an extract from a stem or a pressed solution and containing medicinal cosmetics (Patent Document 2) effective for improving acne and rough skin, and ghetto extract (mainly essential oil) as an active ingredient (Patent Document 3) and the like have been disclosed, and recently, various effects of ghetto extract such as fibroblast proliferation promoting action, collagen production promoting action, collagenase inhibiting action of ghetto leaf extract have been reported (Non-Patent Document 1). Is attracting attention.
ニガリを皮膚外用剤などに配合する試みは古くからなされており、最近では、ニガリを有効成分として含有する養毛剤(特許文献4)、マグネシウムイオンとカルシウムイオンを特定の比率で含有する化粧料の皮膚の保護能,バリヤ機能回復効果(特許文献5)といった特定の効果に関する発明や、尿素,グリセリン,ミョウバンと併用した皮膚用保湿,保護剤(特許文献6)、魚皮エラスチンと併用した保湿及び皮膚保護効果に優れた皮膚外用剤(特許文献7)、フィトンチッド,キトサンと併用した皮膚状態改善作用を有する組成物(特許文献8)等が開示されている。 Attempts have long been made to incorporate bittern into a topical skin preparation, and recently, a hair nourishing agent containing bittern as an active ingredient (Patent Document 4), cosmetic skin containing magnesium ions and calcium ions in a specific ratio. Invention relating to specific effects such as protective ability, barrier function recovery effect (Patent Document 5), skin moisturizing and protective agent used in combination with urea, glycerin and alum (Patent Document 6), moisturizing and skin combined with fish skin elastin A skin external preparation excellent in protective effect (Patent Document 7), a composition having a skin condition improving action in combination with phytoncide and chitosan (Patent Document 8) and the like are disclosed.
本発明においては、アクネ症状の予防・改善効果に優れるとともに、肌荒れ防止・改善効果、保湿効果に優れた皮膚外用剤を提供することを目的とした。 The object of the present invention is to provide an external preparation for skin that is excellent in preventing and improving acne symptoms, as well as in preventing and improving rough skin, and excellent in moisturizing effect.
上記の課題を解決するべく種々検討した結果、ニガリ及び月桃エキスを必須成分とし、さらにウコンエキス,ニンジンエキス,ヨモギエキスから選択される1種又は2種以上を併用して皮膚外用剤に配合することにより、アクネ症状の予防・改善効果に優れるとともに、肌荒れ防止・改善効果、保湿効果に優れた皮膚外用剤が得られることを見いだし、本発明を完成するに至った。 As a result of various studies to solve the above problems, bittern and moon peach extract are essential ingredients, and further, one or more selected from turmeric extract, carrot extract, mugwort extract are used in combination with a skin external preparation As a result, it was found that a skin external preparation excellent in the prevention / amelioration effect of acne symptoms, skin rough prevention / improvement effect, and moisturizing effect was obtained, and the present invention was completed.
本発明により、アクネ症状の予防・改善効果に優れるとともに、肌荒れ防止・改善効果、保湿効果に優れた皮膚外用剤を得ることができた。 According to the present invention, it was possible to obtain a skin external preparation excellent in acne symptom prevention / amelioration effect and excellent in skin roughening prevention / improvement effect and moisturizing effect.
また本発明に用いるニガリは、海水から食塩を製造するにあたり食塩を晶出させた後の液若しくはその乾燥物である。ニガリの組成は、製塩法(イオン交換膜法、天日法、塩田法若しくは蒸発法)の相違、食塩晶出時の温度、食塩晶出時の食塩濃度及び圧力その他の条件によって変わってくる。表1に製塩法が相違するニガリの組成の一例を示す(非特許文献1「無機工業概論」(株)培風館、1995発行、p38〜39)。なお、表1の数値の単位はg/100gである。また、イオン交換膜法によるニガリについてみれば、イオン交換膜の特性等によっても変わってくる。 The bittern used in the present invention is a liquid obtained by crystallization of sodium chloride from seawater or a dried product thereof. The composition of bittern varies depending on the salt production method (ion exchange membrane method, solar method, salt field method or evaporation method), temperature at the time of salt crystallization, salt concentration and pressure at the time of salt crystallization, and other conditions. Table 1 shows an example of the composition of bittern with different salt production methods (Non-patent Document 1 “Inorganic Industry Overview”, Baifukan Co., Ltd., 1995, p38-39). In addition, the unit of the numerical value of Table 1 is g / 100g. In addition, regarding the bittern by the ion exchange membrane method, it varies depending on the characteristics of the ion exchange membrane.
本発明において用いるニガリは、海水から食塩を製造するにあたり食塩を晶出させた後の液若しくはその乾燥物、若しくは人為的にミネラル分を混合したものを用いる。ニガリの組成は、産地、製塩法(イオン交換膜法、天日法、塩田法若しくは蒸発法)の相違、食塩晶出時の温度、食塩晶出時の食塩濃度及び圧力その他の条件によって変わってくるが、奄美群島周辺海域、若しくは南大東島周辺海域で採取した海水を原料として調製したニガリは、海水中に含まれる有機リン酸化合物等の汚染物質の混入が無く、高い角質層改善効果が得られる。 The bittern used in the present invention is a solution obtained by crystallization of salt from seawater, a dried product thereof, or an artificially mixed mineral. The composition of bittern varies depending on the production area, salt production method (ion exchange membrane method, sun method, salt field method or evaporation method), temperature at the time of salt crystallization, salt concentration and pressure at the time of salt crystallization, and other conditions. Nigari, which is prepared from seawater collected in the waters around Amami Islands or Minami Daito Island, is free from contamination by organic phosphate compounds and other substances contained in seawater and has a high stratum corneum improvement effect. It is done.
本発明におけるニガリの配合量は、皮膚外用剤全量に対し、0.001〜5重量%、好ましくは0.005〜1重量%である。 The amount of bittern in the present invention is 0.001 to 5% by weight, preferably 0.005 to 1% by weight, based on the total amount of the external preparation for skin.
ゲットウ(Alpinia speciosa (Wendl.) K. Schum.)は、別名サンニンとも呼ばれるショウガ(Zingiberaceae)科ハナミョウガ(Alpinia)属の植物で、葉から得られる精油成分には抗酸化作用,防腐作用,消臭作用,防虫作用があることが知られ、沖縄などで古くから利用されている植物であり、また、ゲットウの精油成分の分析,精油の利用方法についても数多くの報告がなされている。 Alpinia zerumbet (Alpinia speciosa (Wendl.) K. Schum.) Is the ginger (Zingiberaceae) family Hanamyouga (Alpinia) plants in the genus also called alias Sannin, antioxidant effect on the essential oil component obtained from leaves, antiseptic, deodorant It is known to have action and insect repellent action, and it has been used for a long time in Okinawa. Many reports have been made on the analysis of the essential oil components of ghetto and how to use the essential oil.
本発明においては、ゲットウの葉,茎,花,根の各部位や全草より得られるエキスを、各々、適宜選択して用いることができるが、アクネ菌に対する抗菌効果の点から、葉からのエキスを用いることが好ましい。 In the present invention, extracts obtained from leaves, stems, flowers, roots and whole plants of ghetto can be selected and used, respectively, but from the point of antibacterial effect against acne bacteria, It is preferable to use an extract.
本発明におけるゲットウエキスの配合量は、皮膚外用剤全量に対し、0.01〜1重量%、好ましくは0.05〜1重量%である。 The compounding quantity of the ghetto extract in this invention is 0.01 to 1 weight% with respect to the skin external preparation whole quantity, Preferably it is 0.05 to 1 weight%.
本発明において用いるウコン(Curcuma longa Koen.)は、ショウガ科(Zingiberaceae)に属する多年草で、葉,茎,花,果実,根等の各部位及び全草を用いることができるが、根茎を用いることが好ましい。また、ウコンの根茎を乾燥させたものは「ウコン」と呼ばれる生薬の一種であり、かかる生薬を用いることもできる。 Turmeric ( Curcuma longa Koen.) Used in the present invention is a perennial plant belonging to the family Zingiberaceae , and each part of leaves, stems, flowers, fruits, roots, etc. and whole grass can be used. Is preferred. Further, dried turmeric rhizomes are a kind of herbal medicine called “turmeric”, and such herbal medicine can also be used.
本発明において用いるニンジン(Daucus carota L.)はセリ科(Umbelliferae)に属する越年性草本で、数多くの栽培種が知られている。本発明においては、その保湿及び肌荒れ改善効果の点から、奄美諸島や沖縄諸島で栽培されているシマニンジンを用いることが好ましい。ニンジンは、葉,茎,根等の各部位及び全草を用いることができるが、根部を用いることが好ましい。また、ニンジンエキスとしては、根部を生のまま粉砕後圧搾したものを用いることが好ましい。 The carrot ( Daucus carota L.) used in the present invention is a perennial herb belonging to the Umbelliferae family, and many cultivated species are known. In the present invention, it is preferable to use Shimanin, which is cultivated in the Amami Islands and Okinawa Islands, from the viewpoint of its moisturizing and rough skin improving effects. Carrots can be used in various parts such as leaves, stems, roots, and whole plants, but the roots are preferably used. Moreover, as a carrot extract, it is preferable to use what was crushed and squeezed while the root part was raw.
本発明において用いるヨモギ(Artemisia princeps Pamp.)は、キク科(Compositae)に属する多年草で、葉,茎,花,果実,根等の各部位及び全草を用いることができるが、葉を用いることが好ましい。また、ヨモギの葉を乾燥させたものは「ヨモギ」と呼ばれる生薬の一種であり、かかる生薬を用いることもできる。 Mugwort ( Artemisia princeps Pamp.) Used in the present invention is a perennial plant belonging to the Compositae family, and each part of leaves, stems, flowers, fruits, roots, etc. and whole plants can be used, but leaves are used. Is preferred. Also, dried mugwort leaves are a kind of herbal medicine called “mugwort”, and such herbal medicine can also be used.
本発明においては、ウコンエキス,ニンジンエキス,ヨモギエキスから選択される1種又は2種以上を用いる。これらのエキスの配合量は、それぞれを単品で配合する場合と比較して、より少量の配合で、効果を発揮することができる。具体的には、エキスの配合量は、合計で皮膚外用剤全量に対して0.01〜3重量%、好ましくは0.05〜1重量%である。 In the present invention, one or more selected from turmeric extract, carrot extract, and mugwort extract are used. The blending amount of these extracts can exert an effect with a smaller amount of blending than when blended individually. Specifically, the total amount of the extract is 0.01 to 3% by weight, preferably 0.05 to 1% by weight, based on the total amount of the external preparation for skin.
続いて本発明において用いる植物エキスは、上記各植物をそのまま又は粉砕後、搾取したものか、そのまま又は粉砕後、溶媒で抽出したものである。 Subsequently, the plant extract used in the present invention is one obtained by extracting the above-mentioned plants as they are or after pulverization, or extracted as they are or after being pulverized with a solvent.
植物エキスを抽出する場合、上記各植物は生のまま抽出に供してもよいが、抽出効率を考えると、細切,乾燥,粉砕等の処理を行った後に抽出を行うことが好ましい。抽出は、抽出溶媒に浸漬して行う。抽出効率を上げるため撹拌を行ったり、抽出溶媒中でホモジナイズしてもよい。抽出温度としては、5℃程度から抽出溶媒の沸点以下の温度とするのが適切である。抽出時間は抽出溶媒の種類や抽出温度によっても異なるが、4時間〜14日間程度とするのが適切である。 When extracting a plant extract, the above-mentioned plants may be subjected to extraction as they are, but considering the extraction efficiency, it is preferable to perform extraction after processing such as shredding, drying, and pulverization. Extraction is performed by immersing in an extraction solvent. In order to increase the extraction efficiency, stirring may be performed, or homogenization may be performed in an extraction solvent. The extraction temperature is suitably about 5 ° C. to the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but is suitably about 4 hours to 14 days.
抽出溶媒としては、水の他、メタノール,エタノール,プロパノール,イソプロパノール等の低級アルコール、1,3-ブチレングリコール,プロピレングリコール,ジプロピレングリコール,グリセリン等の多価アルコール、エチルエーテル,プロピルエーテル等のエーテル類、酢酸エチル,酢酸ブチル等のエステル類、アセトン,エチルメチルケトン等のケトン類などの極性有機溶媒を用いることができ、これらより1種又は2種以上を選択して用いる。また、生理食塩水,リン酸緩衝液,リン酸緩衝生理食塩水等を用いてもよい。 Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, and ethers such as ethyl ether and propyl ether. , Polar organic solvents such as esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these are selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used.
上記植物の上記エキスは、そのままでも本発明に係る皮膚外用剤に含有させることができるが、濃縮,乾固したものを水や極性溶媒に再度溶解したり、或いはそれらの皮膚生理機能向上作用を損なわない範囲で脱色,脱臭,脱塩等の精製処理を行ったり、カラムクロマトグラフィーによる分画処理を行った後に用いてもよい。また保存のため、精製処理の後凍結乾燥し、用時に溶媒に溶解して用いることもできる。また、リポソーム等のベシクルやマイクロカプセル等に内包させて用いることもできる。 The above-mentioned extract of the above plant can be contained in the skin external preparation according to the present invention as it is, but the concentrated and dried solid can be dissolved again in water or a polar solvent, or their skin physiological function improving action can be obtained. You may use after performing the refinement | purification processes, such as decoloring, deodorizing, and desalting, in the range which is not impaired, or performing the fractionation process by column chromatography. For storage, it can be freeze-dried after purification and dissolved in a solvent before use. It can also be used by encapsulating in vesicles such as liposomes or microcapsules.
本発明においては、上記したニガリ、ゲットウエキス、及びウコンエキス,ニンジンエキス,ヨモギエキスから選択される1種又は2種以上と併用して、抗炎症剤、角質軟化剤、抗菌剤から選択される1種または2種以上の薬剤を併用して用いることができる。これらの薬剤をニガリ、ゲットウエキス等と併用することにより、薬剤の配合量を減量することが可能となる。 In the present invention, it is selected from anti-inflammatory agents, keratin softeners, and antibacterial agents in combination with one or more selected from the above bittern, ghetto extract, turmeric extract, carrot extract, mugwort extract. One or more drugs can be used in combination. By using these drugs in combination with bittern, ghetto extract, etc., it becomes possible to reduce the amount of the drug.
抗炎症剤としては、コルチゾン,ヒドロコルチゾン,プレドニゾロン,メチルプレドニゾロン,デキサメタゾン,ベタメタゾン,トリアムシノロン,トリアムシノロンアセトニド,フルオシノロンアセトニド,フルオシノニド,ベクロメタゾン及びこれらのリン酸塩,プロピオン酸塩,酢酸塩,コハク酸塩等のステロイド性抗炎症剤、サリチル酸及びアスピリン,サリチルアミド,エテンザミド,サリチル酸メチル等のサリチル酸誘導体、インドメタシン,スリンダク等のインドール酢酸誘導体、フェニルブタゾン,オキシフェンブタゾン等のピラゾリジンジオン誘導体、メフェナム酸,フルフェナム酸等のアントラニル酸誘導体、イブプロフェン,ケトプロフェン,ナプロキセン等のプロピオン酸誘導体、ジクロフェナック,フェンブフェン等のフェニル酢酸誘導体、ピロキシカム等のベンゾチアジン誘導体といった非ステロイド性抗炎症剤、グリチルリチン酸及びグリチルリチン酸ジカリウム,グリチルリチン酸モノアンモニウム等の塩並びに誘導体、グリチルレチン酸及びグリチルレチン酸ステアリル,ステアリン酸グリチルレチニル,3-サクシニルオキシグリチルレチン酸二ナトリウム等の塩並びに誘導体、グアイアズレン,グアイアズレンスルホン酸エチル,グアイアズレンスルホン酸ナトリウム,カマズレン等のアズレン誘導体、アラントイン、アロイン、アロエエモジン、シコニン及びイソブチルシコニン,アセチルシコニン,イソバレリルシコニン等の誘導体、ギンセノシドRa1,ギンセノシドRa2,ギンセノシドRb1等のギンセノシド,及び20-グルコギンセノシドRf等のギンセノシド誘導体、ペオニフロリン、ペオノール及びペオノシド,ペオノリド等のペオノール誘導体などが挙げられる。 Anti-inflammatory agents include cortisone, hydrocortisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, beclomethasone and their phosphates, propionate, acetate, succinic acid Steroidal anti-inflammatory agents such as salts, salicylic acid and aspirin, salicylamide, etenzamide, salicylic acid derivatives such as methyl salicylate, indoleacetic acid derivatives such as indomethacin and sulindac, pyrazolidinedione derivatives such as phenylbutazone and oxyphenbutazone, Anthranilic acid derivatives such as mefenamic acid and flufenamic acid, propionic acid derivatives such as ibuprofen, ketoprofen, naproxen, diclofenac, fenbufe Non-steroidal anti-inflammatory drugs such as phenylacetic acid derivatives such as benzothiazine derivatives such as piroxicam, salts and derivatives such as glycyrrhizic acid and dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, glycyrrhetinic acid and stearyl glycyrrhetinate, glycyrrhetinyl stearate, 3-succinyl Salts and derivatives such as disodium oxyglycyrrhetinate, azulene derivatives such as guaiazulene, ethyl guaiazulene sulfonate, sodium guaiazulene sulfonate, camazulene, derivatives such as allantoin, aloin, aloe emodin, shikonin and isobutyl shikonin, acetyl shikonin, isovaleryl shikonin , Ginsenoside Ra1, ginsenoside Ra2, ginsenoside Rb1, etc., and 20-glucoginosenoside R Examples include ginsenoside derivatives such as f, paeoniflorin, peonol, and peonol derivatives such as peonoside and peonolide.
また本発明においては抗炎症剤として、シコン(Lithospermi Radix),オタネニンジン(Ginseng Radix),クジン(Sophorae Radix),カンゾウ(Glycyrrhizae Radix)等、抗炎症剤として用いられる生薬からのエキスを用いることもできる。 In the present invention, as an anti-inflammatory agent, an extract from a herbal medicine used as an anti-inflammatory agent such as shikon ( Lithospermi Radix ), ginseng ( Ginseng Radix ), kudin ( Sophorae Radix ), licorice ( Glycyrrhizae Radix ) can also be used. .
これらの抗炎症剤の含有量は、充分なアクネ予防・改善効果を示すために、皮膚外用剤全量に対し0.001〜5重量%、好ましくは0.01〜2重量%配合する。 The content of these anti-inflammatory agents is 0.001 to 5% by weight, preferably 0.01 to 2% by weight, based on the total amount of the external preparation for skin, in order to exhibit a sufficient acne prevention / amelioration effect.
角質軟化剤としては、グリコール酸、グリコール酸塩、クエン酸、クエン酸塩、乳酸、乳酸塩、尿素、イオウ、サリチル酸、サリチル酸塩などが挙げられる。これらのうち、皮膚に対する低刺激性や使用前例などの点から、乳酸、乳酸塩、尿素、サリチル酸を用いることが好ましく、これらのうち一種もしくは二種以上配合することができる。これらの角質軟化剤の配合量はその有効性の点から、皮膚外用剤全量に対し、グリコール酸、グリコール酸塩、クエン酸、クエン酸塩、乳酸、乳酸塩の場合には0.01〜1重量%、尿素の場合には0.5〜10重量%、イオウ、サリチル酸、サリチル酸塩の場合には0.01〜1重量%程度の配合量とすることが好ましい。 Examples of the keratin softener include glycolic acid, glycolate, citric acid, citrate, lactic acid, lactate, urea, sulfur, salicylic acid, and salicylate. Of these, lactic acid, lactate, urea, and salicylic acid are preferably used from the viewpoint of low irritation to the skin and pre-use examples, and one or more of these can be blended. The blending amount of these keratin softeners is 0.01 to 1 in the case of glycolic acid, glycolate, citric acid, citrate, lactic acid, lactate with respect to the total amount of the external preparation for skin because of its effectiveness. In the case of weight% and urea, the blending amount is preferably about 0.5 to 10% by weight, and in the case of sulfur, salicylic acid and salicylate, the amount is preferably about 0.01 to 1% by weight.
抗菌剤としては、アクネ菌の生育を抑えるという機能を有し、かつ皮膚外用剤の配合成分として安全性等の面で適切であれば特に限定されるものではない。具体的には、抗菌を目的として用いられている成分、例えば、オウバク抽出液、ヒノキチオール、トリクロサン、トリクロロカルバニリド、クロルヘキシジン塩酸塩、クロルヘキシジングルコンサン塩、ハロカルバン、クロロフェネシン、塩化ベンゼトニウム、塩化ベンザルコニウム、塩化リゾチーム、塩酸アルキルジアミノエチルグリシン、イソプロピルメチルフェノール、安息香酸、感光素201号、チモール、ヘキサクロロフェン、ベルベリン、チオキソロンおよびそれらの誘導体を挙げることができる。 The antibacterial agent is not particularly limited as long as it has a function of suppressing the growth of acne bacteria and is suitable as a component of the external preparation for skin in terms of safety and the like. Specifically, components used for antibacterial purposes, such as agaric extract, hinokitiol, triclosan, trichlorocarbanilide, chlorhexidine hydrochloride, chlorhexidine glucosane salt, halocarban, chlorophenesin, benzethonium chloride, chloride Mention may be made of benzalkonium chloride, lysozyme chloride, alkyldiaminoethylglycine hydrochloride, isopropylmethylphenol, benzoic acid, photosensitizer 201, thymol, hexachlorophene, berberine, thioxolone and their derivatives.
これらの抗菌剤は、単独で又は必要に応じて2種以上を組み合わせて本発明の皮膚外用剤に配合することができる。化粧料中における抗菌剤の含有量は、充分なアクネ予防・改善効果を示すために、皮膚外用剤全量に対し0.001〜5重量%、好ましくは0.01〜2重量%配合する。 These antibacterial agents can be blended in the skin external preparation of the present invention alone or in combination of two or more as required. The content of the antibacterial agent in the cosmetic is 0.001 to 5% by weight, preferably 0.01 to 2% by weight, based on the total amount of the external preparation for skin, in order to exhibit a sufficient acne prevention / amelioration effect.
本発明に係る皮膚外用剤は、ローション剤,乳剤,ゲル剤,クリーム剤,軟膏剤,粉末剤,顆粒剤等、種々の剤型で提供することができる。また、化粧水,乳液,クリーム,美容液,パック等の皮膚化粧料、メイクアップベースローション,メイクアップベースクリーム等の下地化粧料、乳液状,油性,固形状等の各剤型のファンデーション,アイカラー,チークカラー等のメイクアップ化粧料、クレンジングクリーム,クレンジングローション,クレンジングフォーム,洗顔石鹸,ボディシャンプー等の皮膚洗浄料等としても提供することができる。 The external preparation for skin according to the present invention can be provided in various dosage forms such as lotions, emulsions, gels, creams, ointments, powders, granules and the like. In addition, skin cosmetics such as lotion, milky lotion, cream, beauty essence, packs, foundation cosmetics such as makeup base lotion and makeup base cream, foundations for each dosage form such as emulsion, oily, solid, etc. It can also be provided as makeup cosmetics such as color and cheek color, skin cleansing agents such as cleansing creams, cleansing lotions, cleansing foams, facial soaps and body shampoos.
なお本発明に係る皮膚外用剤には、上記必須成分の他に、油性成分,界面活性剤,保湿剤,顔料,紫外線吸収剤,抗酸化剤,香料,防菌防黴剤等の一般的な医薬品及び化粧料用原料や、皮膚細胞賦活剤,美白剤等の生理活性成分をも含有させることができる。 The external preparation for skin according to the present invention includes general components such as oil components, surfactants, moisturizers, pigments, ultraviolet absorbers, antioxidants, fragrances, antibacterial and antifungal agents in addition to the above essential components. Bioactive ingredients such as pharmaceutical and cosmetic raw materials, skin cell activators, and whitening agents can also be included.
更に、実施例により、本発明の特徴について詳細に説明する。まず、各実施例で使用したニガリ及び各植物エキスの製造例を示す。 Further, the features of the present invention will be described in detail by way of examples. First, the manufacturing example of the bittern used in each Example and each plant extract is shown.
[製造例1] 奄美群島ニガリ
奄美群島周辺海域で採取した海水を、ポリアミド系複合逆浸透膜を用いてかん水を調製した。得られたかん水を、110℃で加熱しニガリと塩に分離することにより、トカラニガリを得た。
[Production Example 1] Amami Islands Nigari Brine was prepared from seawater collected in the waters around Amami Islands using a polyamide composite reverse osmosis membrane. The resulting brine was heated at 110 ° C. to separate it into bittern and salt, thereby obtaining Tokaranigari.
[製造例2] 南大東島ニガリ
南大東島周辺海域で採取した海水を、ポリアミド系複合逆浸透膜を用いてかん水を調製した。得られたかん水を、113℃で加熱しニガリと塩に分離することにより、南大東島ニガリを得た。
[Manufacturing Example 2] Nigori Daito Island Nigali Brine was prepared from seawater collected in the sea area around Minami Daito Island using a polyamide composite reverse osmosis membrane. The obtained brackish water was heated at 113 ° C. to separate into bittern and salt, thereby obtaining Minami Daitojima bittern.
[調製例3〜5]
表2に示した植物各200gを乾燥,粉砕し、50容量%エタノール水溶液各2リットル中にて室温7日間撹拌抽出した後、ろ過してろ液を回収し、ロータリーエバポレーターにて減圧濃縮し、更に凍結乾燥させ各植物エキスを得た。
[Preparation Examples 3 to 5]
200 g of each plant shown in Table 2 was dried and pulverized, extracted by stirring in 2 liters of 50% by volume ethanol aqueous solution for 7 days at room temperature, filtered to collect the filtrate, concentrated under reduced pressure using a rotary evaporator, Each plant extract was obtained by freeze-drying.
[製造例6] ニンジンエキス
採取したシマニンジンの根部を水洗し、そのままプロセッサーで粉砕後ろ過する。ろ液を等容量のグリセリンに分散させ、ニンジンエキスを得た。
[Production Example 6] Carrot extract The collected root of the carrot is washed with water, pulverized as it is with a processor, and then filtered. The filtrate was dispersed in an equal volume of glycerin to obtain a carrot extract.
続いて、上記調製例を配合した実施例を示す。 Then, the Example which mix | blended the said preparation example is shown.
[実施例1〜5,比較例1〜4]
表3又は表4に示す組成で、全成分を均一に混合して化粧料を得た。得られた化粧料を用いてアクネケア効果、肌荒れ改善効果、保湿効果の評価を行った。
[Examples 1 to 5, Comparative Examples 1 to 4]
With the composition shown in Table 3 or Table 4, all ingredients were mixed uniformly to obtain a cosmetic. Acne care effect, rough skin improvement effect, and moisturizing effect were evaluated using the obtained cosmetics.
(評価方法)
15歳〜40歳までのアクネ及び肌荒れ,乾燥に悩む混合肌の女性20名を一群として、実施例若しくは比較例をブラインドにて使用させた。使用方法は、洗顔料を用いて顔面をよく洗浄した後、全顔に各々の化粧料を1日朝夕2回、4週間塗布させた。使用前後の肌を写真撮影して比較することにより、アクネケア効果及び肌荒れ改善効果を、使用前後の肌の乾燥状態を聞き取り調査することにより保湿効果を、それぞれ評価した。
(Evaluation methods)
Examples or comparative examples were blindly used as a group of 20 women with mixed skin who suffered from acne from 15 to 40 years old and rough skin and dryness. As a method of use, the face was thoroughly washed with a face wash, and then each cosmetic was applied to the entire face twice a day for 4 weeks. The skin before and after use was photographed and compared to evaluate the acne care effect and the rough skin improvement effect, and the moisturizing effect was evaluated by interviewing the dry state of the skin before and after use.
(評価基準)アクネケア効果
アクネ症状の改善状況について、「改善」,「やや改善」,「変化無し」,「悪化」の4段階にて評価し、各評価を得たパネラー数にて表5に示した。
(Evaluation criteria) Acne care effects The improvement status of acne symptoms was evaluated in four stages: "Improved", "Slightly improved", "No change", and "Deteriorated", and Table 5 shows the number of panelists that obtained each evaluation. Indicated.
(評価基準)肌荒れ改善効果
肌荒れ症状の改善状況について、「改善」,「やや改善」,「変化無し」,「悪化」の4段階にて評価し、各評価を得たパネラー数にて表6に示した。
(Evaluation criteria) Rough skin improvement effect The improvement status of rough skin symptoms was evaluated in four stages: "Improved", "Slightly improved", "No change", and "Deteriorated". Table 6 shows the number of panelists that obtained each evaluation. It was shown to.
(評価基準)保湿効果
肌の乾燥状態について使用前を基準に、「しっとりしている」,「変化なし」,「かさついている」の2段階にて評価し、各評価を得たパネラー数にて表7に示した。
(Evaluation criteria) Moisturizing effect The skin dryness is evaluated in two stages, “moist”, “no change”, and “smooth” based on the pre-use condition, and the number of panelists obtained each evaluation. Table 7 shows the results.
表5〜表7に示した通り、本願発明の実施例1〜5使用群においては、各症状が悪化したパネラーはなく、アクネ症状,肌荒れ症状の改善及び乾燥肌解消傾向が認められた。これに対し、ゲットウエキスと、ニガリ,ウコンエキス,ヨモギエキス,ニンジンエキスから選択される1種を実施例の倍量配合した比較例においては、それぞれの症状に改善傾向は認められたものの、対応する実施例より改善したパネラーの数は少ない結果となった。 As shown in Tables 5 to 7, in the use groups of Examples 1 to 5 of the present invention, there were no panelists in which each symptom was deteriorated, and acne symptom, improvement of rough skin symptom and dry skin resolving tendency were recognized. On the other hand, in the comparative example in which one kind selected from ghetto extract and bittern, turmeric extract, mugwort extract, and carrot extract was blended in double the amount of the example, an improvement tendency was observed for each symptom. As a result, the number of improved panelists was smaller than that of the embodiment.
[実施例6] 洗顔フォーム
(1)ミリスチン酸 23.86(重量%)
(2)パルミチン酸 3.28
(3)ステアリン酸 8.33
(4)濃グリセリン 16.00
(5)親油型モノステアリン酸グリセリン 3.00
(6)水酸化カリウム 7.59
(7)精製水 18.00
(8)1,3-ブチレングリコール 3.00
(9)カルボキシメチルセルロースナトリウム 0.03
(10)ヤシ油脂肪酸アミドプロピルベタイン液 3.00
(11)精製水 12.96
(12)製造例1 0.30
(13)製造例3 0.30
(14)製造例4 0.10
(15)製造例5 0.10
(16)製造例6 0.10
(17)香料 0.05
製法:(1)〜(5)の油相成分を混合,加熱溶解して80℃とする。一方(6),(7)の水相成分を混合,加熱溶解して80℃とする。この水相成分に前記油相成分を徐々に添加して中和した後混合し、75℃に加温した(8)〜(11)を加え、冷却して50℃にて(12)〜(17)を添加,混合しながら更に冷却する。
[Example 6] Facial cleansing foam
(1) Myristic acid 23.86 (% by weight)
(2) Palmitic acid 3.28
(3) Stearic acid 8.33
(4) Concentrated glycerin 16.00
(5) Lipophilic glyceryl monostearate 3.00
(6) Potassium hydroxide 7.59
(7) Purified water 18.00
(8) 1,3-butylene glycol 3.00
(9) Carboxymethylcellulose sodium 0.03
(10) Palm oil fatty acid amidopropyl betaine solution 3.00
(11) Purified water 12.96
(12) Production Example 1 0.30
(13) Production Example 3 0.30
(14) Production Example 4 0.10
(15) Production Example 5 0.10
(16) Production Example 6 0.10
(17) Fragrance 0.05
Production method: The oil phase components (1) to (5) are mixed and dissolved by heating to 80 ° C. On the other hand, the aqueous phase components (6) and (7) are mixed and dissolved by heating to 80 ° C. The oil phase component is gradually added to the water phase component to neutralize and then mixed, and (8) to (11) heated to 75 ° C. are added, and cooled to 50 ° C. at (12) to (12) Add 17) and cool further while mixing.
[実施例7] クレンジングマッサージジェル
(1)精製水 11.24(重量%)
(2)濃グリセリン 14.40
(3)ショ糖脂肪酸エステル 5.00
(4)イソステアリン酸ポリオキシエチレングリセリル 2.00
(5)1,3-ブチレングリコール 3.00
(6)パラオキシ安息香酸メチル 0.50
(7)スクワラン 32.05
(8)トリ2-エチルヘキサン酸グリセリル 18.55
(9)ジカプリン酸ネオペンチルグリコール 9.28
(10)ステアリン酸 1.00
(11)精製ホホバ油 1.00
(12)水素添加大豆リン脂質 1.00
(13)製造例2 0.30
(14)製造例3 0.30
(15)製造例4 0.10
(16)製造例5 0.10
(17)製造例6 0.10
(18)香料 0.08
製法:(7)〜(12)の油相成分を混合,加熱溶解して70℃とする。一方(1)〜(6)の水相成分を混合,加熱溶解して70℃とする。この水相成分に前記油相成分を徐々に添加して予備乳化した後、ホモミキサーにて均一に乳化し、冷却して50℃にて(13)〜(18)を添加,混合しながら更に冷却する。
[Example 7] Cleansing Massage Gel
(1) Purified water 11.24 (wt%)
(2) Concentrated glycerin 14.40
(3) Sucrose fatty acid ester 5.00
(4) Polyoxyethylene glyceryl isostearate 2.00
(5) 1,3-butylene glycol 3.00
(6) Methyl paraoxybenzoate 0.50
(7) Squalane 32.05
(8) Glyceryl tri-2-ethylhexanoate 18.55
(9) Neopentyl glycol dicaprate 9.28
(10) Stearic acid 1.00
(11) Refined jojoba oil 1.00
(12) Hydrogenated soybean phospholipid 1.00
(13) Production Example 2 0.30
(14) Production Example 3 0.30
(15) Production Example 4 0.10
(16) Production Example 5 0.10
(17) Production Example 6 0.10
(18) Perfume 0.08
Production method: The oil phase components (7) to (12) are mixed and dissolved by heating to 70 ° C. On the other hand, the aqueous phase components (1) to (6) are mixed and dissolved by heating to 70 ° C. The oil phase component is gradually added to this aqueous phase component and pre-emulsified, and then uniformly emulsified with a homomixer, cooled and further added with (13) to (18) at 50 ° C. while mixing. Cooling.
[実施例8] パック
(1)精製水 68.07(重量%)
(2)濃グリセリン 5.00
(3)ポリエチレングリコール(平均分子量1540) 3.00
(4)パラオキシ安息香酸メチル 0.02
(5)ポリビニルアルコール 12.90
(6)無水ケイ酸 0.06
(7)エタノール 10.00
(8)製造例1 0.30
(9)製造例3 0.30
(10)製造例4 0.10
(11)製造例5 0.10
(12)製造例6 0.10
(13)香料 0.05
製法:(1)に(2)から(13)の成分を順次混合,溶解する。
[Example 8] Pack
(1) Purified water 68.07 (% by weight)
(2) Concentrated glycerin 5.00
(3) Polyethylene glycol (average molecular weight 1540) 3.00
(4) Methyl paraoxybenzoate 0.02
(5) Polyvinyl alcohol 12.90
(6) Silicic anhydride 0.06
(7) Ethanol 10.00
(8) Production Example 1 0.30
(9) Production Example 3 0.30
(10) Production Example 4 0.10
(11) Production Example 5 0.10
(12) Production Example 6 0.10
(13) Fragrance 0.05
Production method: Components (2) to (13) are sequentially mixed and dissolved in (1).
[実施例9]化粧水
(1)精製水 83.19(重量%)
(2)ポリオキシエチレン(50)硬化ヒマシ油 0.05
(3)1,3−ブチレングリコール 7.00
(4)サリチル酸 0.05
(5)エタノール 4.50
(6)ジグリセリン 2.50
(7)クエン酸ナトリウム 0.23
(8)クエン酸 0.03
(9)ハチミツ 0.20
(10)パラオキシ安息香酸メチル 0.20
(11)アラントイン 0.10
(12)製造例2 1.00
(13)製造例3 0.50
(14)製造例4 0.10
(15)製造例5 0.10
(16)製造例6 0.10
(17)マルチトール 0.10
(18)香料 0.05
製法:(1)に(2)〜(18)の成分を順次混合、溶解する。
[Example 9] Lotion
(1) Purified water 83.19 (wt%)
(2) Polyoxyethylene (50) hydrogenated castor oil 0.05
(3) 1,3-butylene glycol 7.00
(4) Salicylic acid 0.05
(5) Ethanol 4.50
(6) Diglycerin 2.50
(7) Sodium citrate 0.23
(8) Citric acid 0.03
(9) Honey 0.20
(10) Methyl paraoxybenzoate 0.20
(11) Allantoin 0.10
(12) Production Example 2 1.00
(13) Production Example 3 0.50
(14) Production Example 4 0.10
(15) Production Example 5 0.10
(16) Production Example 6 0.10
(17) Maltitol 0.10
(18) Fragrance 0.05
Production method: Components (2) to (18) are sequentially mixed and dissolved in (1).
[実施例10] 美容液
(1)精製水 68.36(重量%)
(2)ポリオキシエチレン(50)硬化ヒマシ油 0.05
(3)ポリエチレングリコール 1.40
(4)ルチン配糖体 0.05
(5)マルチトール 0.20
(6)エタノール 7.00
(7)パラオキシ安息香酸メチル 0.10
(8)1,3−ブチレングリコール 7.00
(9)グリチルリチン酸ジカリウム 0.10
(10)カルボキシビニルポリマー(1重量%水溶液) 10.00
(11)キサンタンガム(2重量%水溶液) 5.00
(12)製造例1 0.50
(13)製造例3 0.05
(14)製造例4 0.05
(15)製造例5 0.01
(16)製造例6 0.01
(17)香料 0.02
(18)水酸化ナトリウム(10重量%水溶液) 0.10
製法:(1)に(2)〜(17)の成分を順次添加して溶解した後、(18)で中和する。
[Example 10] Cosmetic liquid
(1) Purified water 68.36 (wt%)
(2) Polyoxyethylene (50) hydrogenated castor oil 0.05
(3) Polyethylene glycol 1.40
(4) Rutin glycoside 0.05
(5) Maltitol 0.20
(6) Ethanol 7.00
(7) Methyl paraoxybenzoate 0.10
(8) 1,3-butylene glycol 7.00
(9) Dipotassium glycyrrhizinate 0.10
(10) Carboxyvinyl polymer (1 wt% aqueous solution) 10.00
(11) Xanthan gum (2% by weight aqueous solution) 5.00
(12) Production Example 1 0.50
(13) Production Example 3 0.05
(14) Production Example 4 0.05
(15) Production Example 5 0.01
(16) Production Example 6 0.01
(17) Perfume 0.02
(18) Sodium hydroxide (10% by weight aqueous solution) 0.10
Production method: Components (2) to (17) are sequentially added to (1) and dissolved, and then neutralized with (18).
Claims (4)
A skin external preparation for moisturizing containing one or more selected from turmeric extract, carrot extract, mugwort extract, bittern and moon peach extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005116080A JP4766907B2 (en) | 2005-04-13 | 2005-04-13 | Topical skin preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005116080A JP4766907B2 (en) | 2005-04-13 | 2005-04-13 | Topical skin preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006290832A true JP2006290832A (en) | 2006-10-26 |
JP4766907B2 JP4766907B2 (en) | 2011-09-07 |
Family
ID=37411787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005116080A Active JP4766907B2 (en) | 2005-04-13 | 2005-04-13 | Topical skin preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4766907B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007254343A (en) * | 2006-03-23 | 2007-10-04 | Naris Cosmetics Co Ltd | Cosmetic containing carrot extract |
JP2008110992A (en) * | 2008-01-29 | 2008-05-15 | Mandom Corp | Antibacterial composition and skin care preparation |
JP2011098901A (en) * | 2009-11-05 | 2011-05-19 | Noevir Co Ltd | Skin care preparation for acne |
JP2012102048A (en) * | 2010-11-10 | 2012-05-31 | Nof Corp | Solid soap composition |
JP2013142083A (en) * | 2012-01-12 | 2013-07-22 | Sunstar Inc | Mugwort extract-containing composition |
CN117695229A (en) * | 2024-02-05 | 2024-03-15 | 广东润洁日化有限公司 | Shikonin curcumin liposome and preparation method and application thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6320880A (en) * | 1986-07-15 | 1988-01-28 | Seiko Instr & Electronics Ltd | Manufacture of thermoelement for electronic wristwatch |
JP2000191493A (en) * | 1998-12-24 | 2000-07-11 | Eikoudou:Kk | Medicated cosmetic |
JP2001288035A (en) * | 2000-03-31 | 2001-10-16 | Kose Corp | External preparation for skin for acne |
JP2003095912A (en) * | 2001-09-20 | 2003-04-03 | Noevir Co Ltd | Skin care preparation |
JP2003261417A (en) * | 2002-03-08 | 2003-09-16 | Noevir Co Ltd | Skin care preparation |
JP2003342122A (en) * | 2002-05-30 | 2003-12-03 | Noevir Co Ltd | Skin care preparation |
JP2004051596A (en) * | 2002-07-24 | 2004-02-19 | Noevir Co Ltd | Agent for promoting biosynthesis of epidermic transglutaminase and activity promoting agent |
JP2004075632A (en) * | 2002-08-21 | 2004-03-11 | Noevir Co Ltd | Dermatofibroblast activator |
JP2004131498A (en) * | 2002-09-18 | 2004-04-30 | Veritas:Kk | External preparation for skin |
JP2004196747A (en) * | 2002-12-20 | 2004-07-15 | Hamamatsu Photonics Kk | Cleaning solution |
JP2004250690A (en) * | 2003-01-27 | 2004-09-09 | Mitsubishi Corp | Anti-oxidant composition and composition for external use |
-
2005
- 2005-04-13 JP JP2005116080A patent/JP4766907B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6320880A (en) * | 1986-07-15 | 1988-01-28 | Seiko Instr & Electronics Ltd | Manufacture of thermoelement for electronic wristwatch |
JP2000191493A (en) * | 1998-12-24 | 2000-07-11 | Eikoudou:Kk | Medicated cosmetic |
JP2001288035A (en) * | 2000-03-31 | 2001-10-16 | Kose Corp | External preparation for skin for acne |
JP2003095912A (en) * | 2001-09-20 | 2003-04-03 | Noevir Co Ltd | Skin care preparation |
JP2003261417A (en) * | 2002-03-08 | 2003-09-16 | Noevir Co Ltd | Skin care preparation |
JP2003342122A (en) * | 2002-05-30 | 2003-12-03 | Noevir Co Ltd | Skin care preparation |
JP2004051596A (en) * | 2002-07-24 | 2004-02-19 | Noevir Co Ltd | Agent for promoting biosynthesis of epidermic transglutaminase and activity promoting agent |
JP2004075632A (en) * | 2002-08-21 | 2004-03-11 | Noevir Co Ltd | Dermatofibroblast activator |
JP2004131498A (en) * | 2002-09-18 | 2004-04-30 | Veritas:Kk | External preparation for skin |
JP2004196747A (en) * | 2002-12-20 | 2004-07-15 | Hamamatsu Photonics Kk | Cleaning solution |
JP2004250690A (en) * | 2003-01-27 | 2004-09-09 | Mitsubishi Corp | Anti-oxidant composition and composition for external use |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007254343A (en) * | 2006-03-23 | 2007-10-04 | Naris Cosmetics Co Ltd | Cosmetic containing carrot extract |
JP2008110992A (en) * | 2008-01-29 | 2008-05-15 | Mandom Corp | Antibacterial composition and skin care preparation |
JP2011098901A (en) * | 2009-11-05 | 2011-05-19 | Noevir Co Ltd | Skin care preparation for acne |
JP2012102048A (en) * | 2010-11-10 | 2012-05-31 | Nof Corp | Solid soap composition |
JP2013142083A (en) * | 2012-01-12 | 2013-07-22 | Sunstar Inc | Mugwort extract-containing composition |
CN117695229A (en) * | 2024-02-05 | 2024-03-15 | 广东润洁日化有限公司 | Shikonin curcumin liposome and preparation method and application thereof |
CN117695229B (en) * | 2024-02-05 | 2024-04-12 | 广东润洁日化有限公司 | Shikonin curcumin liposome and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP4766907B2 (en) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010132629A (en) | External composition for skin | |
CN1568930A (en) | Method for applying active constitutent of Bunge prickly ash to daily used chemical products | |
JP4766907B2 (en) | Topical skin preparation | |
JP4414495B2 (en) | Antibacterial agent, skin external preparation and skin cleansing agent containing the same | |
JP4685374B2 (en) | Topical skin preparation | |
CN105520869B (en) | Composition containing Ginseng radix Rubri concentrate for improving acne | |
Isnaini et al. | Trends in Formulation of Night Cream Containing Essential Oil | |
JP3667291B2 (en) | Topical skin preparation | |
JP2001026518A (en) | Preparation composition for external use for skin | |
KR101034405B1 (en) | Antibiotic composition containing herbal medicine extracts | |
JP2008247786A (en) | External preparation for skin | |
WO2011117126A2 (en) | Skin-friendly active ingredient combination to combat acne | |
JP2003261417A (en) | Skin care preparation | |
JP2001181174A (en) | Cosmetic composition | |
JP3504594B2 (en) | External preparation for skin | |
JP2002145793A (en) | Skin care preparation | |
JP3742281B2 (en) | Topical skin preparation | |
JP2018127407A (en) | Epidermis normalization agent as well as external preparations and cosmetics containing the same | |
JP2008247787A (en) | External preparation for skin | |
JP3447667B2 (en) | External preparation for skin | |
US20010014314A1 (en) | Foot soap composition | |
JP3719951B2 (en) | Skin preparation | |
JP4222973B2 (en) | Elastase activity inhibitors and cosmetics | |
BR102019011197A2 (en) | TOPIC COMPOSITION CONTAINING GLYCERIN AND YEAST EXTRACT | |
KR20040056079A (en) | Cosmetic composition for preventing and therapeutic for a pimple |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20070601 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080407 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091022 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100720 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100921 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110614 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110614 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4766907 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140624 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |